Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Immunisation, Rash erythematous, Rash papular, Vaccination site erythema, Vaccination site pruritus
Clinical narrative: Increasing warmth and itchiness s/p 24 hours.; Iincreasing warmth and itchiness s/p 24 hours.; red symmetrical raised area around injection site, warm to touch, extremely itchy. Noticed red, raised area s/p taking off bandage.; red symmetrical raised area around injection site, warm to touch, extremely itchy. Noticed red, raised area s/p taking off bandage.; red symmetrical raised area around injection site, warm to touch, extremely itchy. Noticed red, raised area s/p taking off bandage.; Booster; This is a spontaneous report from a contactable other health care professional, the patient. A 35-year-old non-pregnant female patient received third (booster) dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FF8839) via an unspecified route of administration in the left arm on 15Oct2021 at 15:00 (at the age of 35-year-old) as a single dose for COVID-19 immunisation. Medical history included hypertension, anxiety and attention deficit-hyperactivity disorder (ADHD). Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included acetylsalicylic acid/ caffeine/salicylamide (EXCEDRIN); amfetamine aspartate/ amfetamine sulfate/ dexamfetamine saccharate/ dexamfetamine sulfate (ADDERALL); cetirizine hydrochloride (ZYRTEC); vitamin d nos (unspecified); escitalopram oxalate (LEXAPRO) and ethinylestradiol/ ferrous fumarate/ norethisterone acetate (LO LOESTRIN FE); all for an unknown indication from an unknown date and unknown if ongoing. The patient did not receive other vaccines within four weeks prior to the COVID vaccine. The patient previously received codeine (MANUFACTURER UNKNOWN) and experienced drug allergy. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EL9265) via an unspecified route of administration in the left arm on 28Jan2021 at 15:00 as a single dose for COVID-19 immunisation and second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EN6200) via an unspecified route of administration in the left arm on 19Feb2021 at 09:45 (at the age of 35-years-old) as a single dose for COVID-19 immunisation and experienced no adverse reactions for both the doses (reported as no noticeable symptoms). On 15Oct2021 at 23:00, the patient experienced a red symmetrical raised area around the injection site, warm to touch, extremely itchy. Noticed red, raised area status post (s/p) taking off a bandage. On 16Oct2021, status post (s/p) 24 hours, the patient experienced increasing warmth and itchiness. It was reported that if the physician's office were open, she would contact them with respect to the intensity of itching and heat of the arm. It was unknown if therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events red symmetrical raised area around the injection site, warm to touch, extremely itchy, noticed red, raised area s/p taking off the bandage, increasing warmth and itchiness was not resolved at the time of this report.